Impact of Priority Review Voucher Eligibility on Research and Development of Medical Countermeasures

Stephanie Wang,Georg Hahn,Aaron S. Kesselheim
DOI: https://doi.org/10.1002/cpt.3388
2024-07-23
Clinical Pharmacology & Therapeutics
Abstract:The priority review voucher was established to incentivize research and development of treatments for traditionally underfunded diseases and was extended to medical countermeasures from 2016 to 2023, despite limited evidence of an association between the voucher program and increased product development. To determine whether the voucher program has incentivized initiation of new medical countermeasures in clinical trials, we created three cohorts of material threats: (i) COVID‐19, (ii) opioid pharmaceutical‐based agents, and (iii) all others. Using the Citeline Trialtrove database, we determined the number of medical countermeasures initiated in clinical trials from 2009–2016 and 2017–2023. Eligibility of COVID‐19 products for the voucher was confirmed with the issuance of a voucher for remdesivir in October 2020, so we compared January 2020–October 2020 to November 2020–July 2023. We fit two Poisson models—before and after voucher creation—within each cohort. Among COVID‐19 medical countermeasures, there was a decrease in the proportion of drugs initiated before (4.5%; 95% CI, 1.0 to 8.3%) vs. after voucher eligibility (−5.1%; 95% CI, −6.1 to −4.0%) ( P = 0.01). Among opioid pharmaceutical‐based agents medical countermeasures, the rate of new drugs initiated did not change from 2009–2016 (8.1%, 95% CI, −4.4 to 22.6%) to 2017–2023 (5.6%; 95% CI, −3.2 to 15.2%) ( P = 0.82). Among all other medical countermeasures, the rate of new drugs initiated also did not change from 2009–2016 (6.6%; 95% CI, −5.6 to 20.8%) to 2017–2023 (−14.8%; 95% CI, −29.2 to 2.0%) ( P = 0.15). The priority review voucher program was not associated with stimulating new clinical testing of investigational medical countermeasures.
pharmacology & pharmacy
What problem does this paper attempt to address?